Oxemiatm Is A Hypoxia-Inducible Factor-Prolyl Hydroxylase (Hif-Ph) Inhibitor That Is Taken Orally. In The Dream-D And Dream-Nd Phase Iii Clinical Trials, Desidustat Met Its Primary Endpoints For Haemoglobin Improvement And Demonstrated A Good Safety Profile, As Well As Down Regulation Of Hepcidin, Improved Iron Mobilisation, And Ldl-C Reduction In Ckd Patients Zydus Lifesciences Announced That The Drug Controller General Of India (Dcgi) Has Accepted Its New Drug Application (Nda) For Oxemia (Desidustat), A First-Ofits-Kind Oral Medication For Anaemia Caused By Chronic Kidney Disease.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!